SANUWAVE Announces Record Quarterly Revenues: Q4 FY2024 Financial Results
Q4 2024 revenues were $10.3 million, up 47% from Q4 2023. This was an all-time quarterly record for the Company.
Full year 2024 revenues were $32.6 million, up 60% from full year 2023 revenues. This was an all-time annual record for the Company.
Q4 2024 gross margin was 77.9%, versus 69.1% in Q4 2023 and 75.5% in Q3 2024.
Full year 2024 gross margin was 75.2% versus 70.4% in 2023.
GAAP Operating Income was $2.5 million for Q4 2024 and $5.4 million for full year 2024.
Company provides guidance for revenue growth of 45-55% for Q1 2025 as compared to Q1 2024 and initiates full year 2025 revenue guidance of $48-50 million for full year 2025 (an increase of 47-53% versus 2024)
EDEN PRAIRIE, Minn., March 21, 2025 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (the "Company" or "Sanuwave") (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to provide its financial results for the three months and for the full year ended December 31, 2024.
Q4 2024 ended December 31, 2024
-- Revenue for the three months ended December 31, 2024, totaled $10.3
million, an increase of 47%, as compared to $7.0 million for the same
period of 2023. This growth is consistent with guidance of growth of
40-50% year on year for the quarter.
-- 135 UltraMist$(R)$ systems were sold in Q4 2024 up from 79 in Q4 2023 and
from 124 in Q3 2024.
-- UltraMist(R) consumables revenue increased by 59% to $5.9 million in Q4
2024 versus $3.7 million for the same quarter last year. Consumables
revenue represented 58% of overall revenues in Q4 2024. UltraMIST systems
and consumables remained the primary revenue growth driver for the
Company and represented over 99% of SANUWAVE's overall revenues in Q4
2024.
-- Gross margin as a percentage of revenue amounted to 77.9% for the three
months ended December 31, 2024, versus 69.1% for the same period last
year.
-- For the three months ended December 31, 2024, operating income totaled
$2.5 million, an increase of $1.5 million, or 143%, compared to Q4 2023,
primarily as a result of the Company's continued efforts to drive
profitable growth and manage expenses.
-- Net loss for the fourth quarter of 2024 was $12.7 million, driven
predominantly by the change in the fair value of derivative liabilities,
valuation adjustments resulting from the share and warrant exchange, and
the extinguishment of debt. This compares to a net profit of $18.2
million in the fourth quarter of 2023, which was primarily driven by the
change in the fair value of derivative liabilities.
-- Adjusted EBITDA [1] for the three months ended December 31, 2024, was
$3.7 million versus Adjusted EBITDA of $0.7 million for the same period
last year, an improvement of $3.0 million.
Full year 2024 ended December 31, 2024
-- Revenue for the year ended December 31, 2024, totaled $32.6 million, an
increase of 60%, as compared to $20.4 million for the same period of
2023. This growth exceeded full year guidance of growth of 50% year on
year.
-- 374 UltraMist(R) systems were sold in 2024 up from 211 in 2023.
-- UltraMist(R) consumables revenue increased by 67% to $20.1 million (61%
of revenues) in 2024, versus $12.0 million for the same period last year.
UltraMIST systems and consumables remained the primary revenue growth
driver and continued to represent over 98% of SANUWAVE's overall revenues
in 2024.
-- Gross margin as a percentage of revenue amounted to 75.2% for the year
ended December 31, 2024, versus 70.4% for the same period last year.
-- For the year ended December 31, 2024, operating income totaled $5.4
million, an increase of $6.0 million compared to full year 2023.
-- Net loss for 2024 was $31.4 million, driven predominantly by the change
in the fair value of derivative liabilities. This compares to a net loss
of $25.8 million in 2023, which was primarily driven by the change in the
fair value of derivative liabilities.
-- Adjusted EBITDA [1] for the twelve months ended December 31, 2024, was
$7.2 million versus Adjusted EBITDA of negative $1.2 million for the same
period last year, an improvement of $8.4 million.
"The fourth quarter once more setting an all-time record for quarterly revenue was a fitting end to a transformational year at Sanuwave," said Morgan Frank, CEO. "Obviously, we're very pleased with these results both for the quarter, and for the year as a whole. We're especially excited about our gains in gross margin and adjusted EBITDA, allowing us to continue the trend of having positive cash flows from operations even after cash interest expense that we began in Q3 2024. This feels like turning a corner. After the "pig through a python" quarter in Q3, Q4 was a quarter without any exceptionally large orders where no customer exceeded 7% of revenues and yet UltraMIST system sales in Q4 still exceeded those in Q3 and set another all-time quarterly record, increasing over 70% from Q4 2023. We are confident that our revenue pipeline is stronger than it has ever been and have been ramping up our sales force and sales strategy to meet this opportunity and to effectively manage the larger customers with whom we continue to engage. Having greatly simplified our capital structure in October 2024 and now having uplisted to the Nasdaq Global Market in March of this year, 2025 shows every sign of being a breakout year for Sanuwave. We look forward to sharing our further progress with you in future quarters."
Financial Outlook
The Company forecasts Q1 2025 revenue of $8.4 to $9.0 million (45-55% increase from Q1 2024) and initiates full year 2025 revenue guidance of $48-50 million (47-53% increase as compared to full year 2024 revenue).
During Q4 2024, the Company effected a 1-for-375 reverse stock split on October 18, 2024, completed its note and warrant exchange, and raised $10.3 million in a private placement, simplifying the Company's capital structure and leaving it with approximately 8.5 million basic shares outstanding. Details of this transaction can be found on the Sanuwave website https://sanuwave.com/investors/press-release-details?newsId=OxzYFl0t620enXp1VyUG or in its filings with the SEC.
As previously announced, a business update will occur via conference call on March 21, 2025 at 8:30 a.m. EST. Materials for the conference call are included on the Company's website at http://www.sanuwave.com/investors.
Telephone access to the call will be available by dialing the following numbers:
Toll Free:1-800-245-3047
Toll/International: 1-203-518-9765
Conference ID: SANUWAVE
OR click the link for instant telephone access to the event.
https://viavid.webcasts.com/starthere.jsp?ei=1703280&tp_key=c099e4f4d9
A replay will be made available through April 11, 2025:
Toll-Free: 1-844-512-2921
Toll/International: 1-412-317-6671
Replay Access ID: 11157832
[1] This is a non-GAAP financial measure. Refer to "Non-GAAP Financial Measures" and the reconciliations in this release for further information.
About SANUWAVE
SANUWAVE Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.
SANUWAVE's end-to-end wound care portfolio of regenerative medicine products and product candidates helps restore the body's normal healing processes. SANUWAVE applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.
Non-GAAP Financial Measures
This press release includes certain financial measures that are not presented in our financial statements prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP"). These financial measures are considered "non-GAAP financial measures" and are intended to supplement, and should not be considered as superior to, or a replacement for, financial measures presented in accordance with U.S. GAAP.
The Company uses Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA") and Adjusted EBITDA to assess its operating performance. Adjusted EBITDA is Earnings before Interest, Taxes, Depreciation and Amortization adjusted for the change in fair value of derivatives and any significant non-cash or infrequent charges. EBITDA and Adjusted EBITDA should not be considered as alternatives to net income (loss) as a measure of financial performance or any other performance measure derived in accordance with U.S. GAAP, and they should not be construed as an inference that the Company's future results will be unaffected by unusual or infrequent items. These non-GAAP financial measures are presented in a consistent manner for each period, unless otherwise disclosed. The Company uses these measures for the purpose of evaluating its historical and prospective financial performance, as well as its performance relative to competitors. These measures also help the Company to make operational and strategic decisions. The Company believes that providing this information to investors, in addition to U.S. GAAP measures, allows them to see the Company's results through the eyes of management, and to better understand its historical and future financial performance. These non-GAAP financial measures are also frequently used by analysts, investors, and other interested parties to evaluate companies in our industry, when considered alongside other U.S. GAAP measures.
EBITDA and Adjusted EBITDA have their limitations as analytical tools, and you should not consider them in isolation or as a substitute for analysis of the Company's results as reported under U.S. GAAP. Some of these limitations are that EBITDA and Adjusted EBITDA:
-- Do not reflect every expenditure, future requirements for capital
expenditures or contractual commitments.
-- Do not reflect all changes in our working capital needs.
-- Do not reflect interest expense, or the amount necessary to service our
outstanding debt.
As presented in the U.S. GAAP to Non-GAAP Reconciliations section below, the Company's non-GAAP financial measures exclude the impact of certain charges that contribute to our net income (loss).
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, and plans for future business development activities. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company's ability to manage its capital resources, competition and the other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
Contact: investors@sanuwave.com
SELECTED FINANCIAL DATA
FOR THE QUARTERS ENDED DECEMBER 2024 AND 2023
(in thousands) 2024 2023
Revenue $ 10,326 $ 6,994
Cost of Revenues 2,285 2,158
------- ------
Gross Margin 8,041 4,836
Gross Margin % 77.9% 69.1%
Total operating expenses 5,519 3,796
Operating Income $ 2,522 $ 1,040
Total other expense (15,243) 17,201
------- ------
Net (Loss) Income Before Income Taxes $(12,721) $18,241
Income tax expense 27 4
------- ------
Net (Loss) Income $(12,748) $18,237
======= ======
NON-GAAP ADJUSTED EBITDA
Three Months Ended December 31,
---------------------------------------
(in thousands) 2024 2023
------------
Net (Loss) Income $ (12,748) $ 18,235
Non-GAAP Adjustments:
Interest expense 2,633 3,119
Depreciation and amortization 409 248
------------- ------------
EBITDA (9,706) 21,602
------------- ------------
Non-GAAP Adjustments for Adjusted
EBITDA:
Change in fair value of
derivative liabilities 13,780 (20,322)
Other non-cash or infrequent
charges:
Gain on extinguishment of debt (1,121) -
Severance agreement and legal
settlement 156 -
Release of historical accrued
expenses (968) (616)
Stock-based compensation 1,514 -
Adjusted EBITDA $ 3,655 $ 664
============= ============
NON-GAAP ADJUSTED EBITDA
For the year ended
----------------------
(in thousands) 2024 2023
-------
Net Loss $(31,372) $(25,807)
Non-GAAP Adjustments:
Interest expense 13,637 15,623
Depreciation and amortization 1,145 1,028
------- -------
EBITDA $(16,590) $ (9,156)
------- -------
Non-GAAP Adjustments for Adjusted EBITDA:
Change in fair value of derivative
liabilities 31,413 9,621
Other non-cash or infrequent charges:
Gain on extinguishment of debt (6,326) -
Severance agreement and legal settlement 741 -
Release of historical accrued expenses (1,547) (1,866)
Stock-based compensation 1,514 -
Shares issued for services - 224
License and option agreement (2,500) -
Prepaid legal fees expensed from
termination of Merger Agreement 457 -
------- -------
Adjusted EBITDA $ 7,162 $ (1,177)
======= =======
CONSOLIDATED BALANCE SHEETS
(In thousands, except share
data) December 31, 2024 December 31, 2023
------------------- ---------------------
ASSETS
Current Assets:
Cash and cash equivalent $ 10,237 $ 1,797
Accounts receivable, net of
allowance of $1,056 and
$1,237, respectively 3,329 3,314
Inventory 4,149 2,951
Prepaid expenses and other
current assets 682 1,722
-------------- --------------
Total Current Assets 18,397 9,784
-------------- --------------
Non-Current Assets:
Property, equipment and
other, net 732 938
Intangible assets, net 3,730 4,434
Goodwill 7,260 7,260
-------------- --------------
Total Non-current Assets 11,722 12,632
Total Assets $ 30,119 $ 22,416
============== ==============
LIABILITIES
Current Liabilities:
Senior secured debt $ 25,305 $ 18,278
Convertible promissory
notes payable -- 5,404
Convertible promissory
notes payable, related
parties -- 1,705
Asset-backed secured
promissory notes payable -- 3,117
Asset-backed secured
promissory notes payable,
related parties -- 1,458
Accounts payable 3,728 5,705
Accrued expenses 4,678 5,999
Factoring liabilities -- 1,490
Warrant liability 8,107 14,447
Accrued interest -- 5,444
Accrued interest, related
parties -- 669
Current portion of contract
liabilities 193 92
Other 334 947
-------------- --------------
Total Current Liabilities 42,345 64,755
-------------- --------------
Non-current Liabilities
Lease liabilities, less
current portion 191 492
Contract liabilities, less
current portion 300 347
-------------- --------------
Total Non-current Liabilities 491 839
Total Liabilities $ 42,836 $ 65,594
============== ==============
STOCKHOLDERS' DEFICIT
Preferred stock, par value
$0.001, 5,000,000 shares
authorized, 6,175 Series A,
293 Series B, 90 Series C, and
8 Series D designated shares,
respectively; no shares issues
and outstanding at 2024 and
2023 $ - $ -
Common stock, par value
$0.001, 2,500,000,000 shares
authorized, 8,543,686 and
3,041,492 issued and
outstanding at 2024 and 2023,
respectively * 9 3
Additional paid-in capital 238,685 176,979
Accumulated deficit (251,421) (220,049)
Accumulated other
comprehensive loss 10 (111)
-------------- --------------
Total Stockholders' Deficit (12,717) (43,178)
-------------- --------------
Total Liabilities and
Stockholders' Deficit $ 30,119 $ 22,416
============== ==============
* Reflects a one-for-three hundred seventy-five (1:375)
reverse stock split of the outstanding shares of the
Company's common stock effected on October 18, 2024.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(In thousands, except share data) Years ended December 31,
------------------------------
2024 2023
---------
Revenue $ 32,634 $ 20,398
Cost of Revenues 8,084 6,035
---------- ---------
Gross Margin 24,550 14,363
---------- ---------
Operating Expenses:
General and administrative 11,348 8,674
Selling and marketing 6,323 4,898
Research and development 673 579
Depreciation and amortization 789 752
---------- ---------
Total Operating Expenses 19,133 14,903
---------- ---------
Operating Income (Loss) 5,417 $(540.SI)$
---------- ---------
Other Income (Expense):
Interest expense (12,423) (12,946)
Interest expense, related party (1,214) (2,677)
Change in fair value of derivative
liabilities (31,413) (9,621)
Gain on extinguishment of debt 6,326 --
Other expense (893) (19)
Other income 2,855 -
---------- ---------
Total Other Expense (36,762) (25,263)
---------- ---------
Net Loss Before Income Taxes (31,345) (25,803)
Income tax expense 27 4
---------- ---------
Net Loss (31,372) (25,807)
========== =========
Other Comprehensive Loss
Foreign currency translation
adjustments 121 (44)
---------- ---------
Total Comprehensive Loss $ (31,251) $ (25,851)
========== =========
Net Loss per share:
Basic and Diluted * $ (7.03) $ (12.19)
Weighted average shares outstanding:
Basic and Diluted * 4,462,883 2,116,936
* Reflects a one-for-three hundred seventy-five (1:375)
reverse stock split of the outstanding shares of the
Company's common stock effected on October 18, 2024.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT
(In thousands, except share data)
Common Stock
-------------------
Number of
Shares Additional Accumulated Other
Issued and Par Paid- in Accumulated Comprehensive
Outstanding* Value Capital Deficit Loss Total
------------ ----- ------------ ------------- ----------------- -----------
Balances as of
December 31,
2022 1,463,300 $ 1 $ 153,298 $ (194,242) $ (67) $(41,010)
Shares issued
for services 34,400 1 526 - - 527
Shares issued
for
settlement of
debt 1,543,792 1 23,155 - - 23,156
Foreign
currency
translation
adjustment - - - - (44) (44)
Net loss - - - (25,807) - (25,807)
------------ ---- -------- -------- ---- ------- -------
Balances as of
December 31,
2023 3,041,492 $ 3 $ 176,979 $ (220,049) $ (111) $(43,178)
============ ==== ======== ======== ==== ======= =======
Sale of common
stock 1,248,489 1 10,299 - - 10,300
Shares issued
for
settlement of
warrants 3,558,396 4 41,380 - - 41,384
Shares issued
for
settlement of
debt 685,737 1 8,513 - - 8,514
Stock-based
compensation 9,572 - 1,514 - - 1,514
Foreign
currency
translation
adjustment - - - - 121 121
Net loss - - - (31,372) - (31,372)
------------ ---- -------- -------- ---- ------- -------
Balance as of
December 31,
2024 8,543,686 $ 9 $ 238,685 $ (251,421) $ 10 $(12,717)
============ ==== ======== ======== ==== ======= =======
* Reflects a one-for-three hundred seventy-five (1:375)
reverse stock split of the outstanding shares of the
Company's common stock effected on October 18, 2024.
CONSOLIDATED STATEMENTS OF CASH FLOWS
Years ended December 31, 2024 and 2023
(In thousands) 2024 2023
------- -------
Cash Flows - Operating Activities:
Net loss $(31,372) $(25,807)
Adjustments to reconcile net loss to net
cash used by operating activities
Stock-based compensation 1,514 -
Depreciation and amortization 1,145 1,028
Reserve for credit losses 77 781
Shares issued for services - 224
Gain on extinguishment of debt (6,326) -
Income tax expense - 4
Change in fair value of derivative
liabilities 31,413 9,621
Amortization of debt issuance and debt
discounts 5,520 6,911
Changes in operating assets and
liabilities
Accounts receivable (486) (53)
Inventory (1,198) (2,800)
Prepaid expenses and other assets (79) (206)
Accounts payable (1,422) 1,546
Accrued interest and accrued interest,
related parties 3,387 6,306
------- -------
Accrued expenses and contract liabilities 282 (2,093)
------- -------
Net Cash Provided by (Used in) Operating
Activities 2,455 (4,538)
Cash Flows - Investing Activities
Proceeds from sale of property and
equipment - 21
Purchases of property and equipment (490) -
------- -------
Net Cash Flows (Used in) Provided by Investing
Activities (490) 21
------- -------
Cash Flows - Financing Activities
Proceeds from convertible promissory notes 1,300 3,026
Payment of note payable (3,548) -
Proceeds from asset-backed secured
promissory notes payable - 2,994
Proceeds from secured promissory notes
payable, related party 500 -
Payments to secured promissory notes
payable, related party $(500.SI)$ -
Payments to factoring (1,490) (639)
Proceeds from sale of common stock 10,300 -
Principal payments on finance leases (208) (170)
------- -------
Net Cash Flows Provided by Financing
Activities 6,354 5,211
------- -------
Effect of Exchange Rates on Cash 121 (50)
------- -------
Net Change in Cash During Period 8,440 644
------- -------
Cash at Beginning of Period 1,797 1,153
------- -------
Cash at End of Period $ 10,237 $ 1,797
======= =======
Supplemental Information:
Cash paid for interest $ 4,311 $ 1,958
Non-Cash Investing and Financing Activities:
Shares issued for settlement of debt 8,513 -
Write off deferred merger costs 1,225 -
Warrants issued in conjunction with
senior secured promissory note payable
and convertible promissory notes
payable 3,557 1,682
Conversion of warrants to common stock 41,380 -
Conversion of convertible notes payable
and accrued interest to common stock - 23,156
Embedded conversion feature on
convertible debt - 835
Common shares issued for advisory shares - 302
Capitalize default interest into senior
secured debt 3,850 -
Conversion of asset-based secured
promissory notes to convertible
promissory notes 4,584 -
(END) Dow Jones Newswires
March 21, 2025 06:00 ET (10:00 GMT)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.